ControlRad, one of the 70+ companies that calls Atlanta Tech Park home, has had a 2019 for the ages.
So far this year, the medical technology company that focuses on reducing radiation exposure during fluoroscopically guided procedures (FGP) announced FDA clearance of its radiation reduction technology in May and also successfully conducted a clinical use of it in September as well.
That’s not all, however!
ControlRad started October by securing $15M in Series B financing from Questa Capital, according to FinSMEs. Questa Capital’s funding also netted ControlRad two new members for its Board of Directors. They are Ryan Drant and Tim Patrick, who both have years of experience in the medical device industry.
ControlRad will put its funding money toward accelerating the commercial launch of the ControlRad Trace System, according to the FinSMEs release. The Trace system is designed to reduce unnecessary radiation by as much as 89% during FGP and can be retrofitted for existing C-arm devices.
